EP0160501A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Sustained release intranasal formulation and method of use thereof
Assignee: Eli Lilly and Co
•
Filing: 1985-04-24
•
Granted: —
•
Expires: 2005-04-24
Abstract
Abstract Administration of a catecholamine by a novel intranasal delivery system provides prolonged blood levels of the drug.
Inventors
- 👤 Kristina Marie Campanale
- 👤 Su Kenneth Shyan-Ell
- 👤 Harve Clark Wilson
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-28 13:50
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0043; A61K31/00; A61K31/13; A61K31/135; A61K47/00; A61K47/06; A61K47/08; A61K47/12; A61K47/14
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
49 words
A sustained release intranasal formulation which comprises a catecholamine, an emulsifying agent, a dispersion medium and a sustained release agent of formula (I): in which R 1 is C 8 -C 10 alkyl or C 8 -C 10 alkenyl; and R is hydrogen or C 1 -C 4 alkyl.
Claim 2
Dependent Claim
49 words
A sustained release intranasal formulation which comprises a catecholamine, an emulsifying agent, a dispersion medium and a sustained release agent of formula (I): in which R 1 is C 8 -C 10 alkyl or C 8 -C 10 alkenyl; and R is hydrogen or C 1 -C 4 alkyl.
Claim 3
Dependent Claim
18 words
A formulation as claimed in Claim 1 in which the catecholamine is dobutamine, or a pharmaceutically-acceptable salt thereof.
Claim 4
Dependent Claim
16 words
A formulation as claimed in Claim 1 or 2 in which the catecholamine is dobutamine hydrochloride.
Claim 5
Dependent Claim
23 words
A formulation as claimed in any one of Claims 1 to 3 in which the emulsifying agent is poloxy- ethylene 20 sorbitan trioleate.
Claim 6
Dependent Claim
25 words
A formulation as claimed in any one of Claims 1 to 4 in which R 1 of formula (I) is C 8 -C 10 alkyl.
Claim 7
Dependent Claim
23 words
A formulation of Claim 5 in which the sustained release agent is oleic acid or a C 1 -C 4 alkyl ester thereof.
Claim 8
Dependent Claim
25 words
A formulation as claimed in any one of Claims 1 to 4 in which R 1 of formula (I) is C 8 -C 10 alkenyl.
Claim 9
Dependent Claim
23 words
A formulation of Claim 7 in which the sustained release agent is linoleic acid, or a C 1 -C 4 alkyl ester thereof.
Claim 10
Dependent Claim
21 words
A sustained release intranasal formulation as claimed in any one of Claims 1 to 8 for use in increasing cardiac contractility.
Claim 11
Dependent Claim
23 words
A sustained release intranasal formulation as claimed in Claim 1 in which the catecholamine is dobutamine hydrochloride for use in increasing cardiac contractility.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.